Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPM8 | Q7Z2W7 | 11/20 | 0.72 |
| ▸ | L3MBTL1 | Q9Y468 | 8/20 | 0.68 |
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.68 |
| ▸ | LMNA | P02545 | 5/20 | 0.68 |
| ▸ | MAPT | P10636 | 3/20 | 0.68 |
| ▸ | MITF | O75030 | 1/20 | 0.68 |
| ▸ | HTT | P42858 | 2/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.58 |
| ▸ | MEN1 | O00255 | 4/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.54 |
| ▸ | PPP1CA | P62136 | 3/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1443842 | 0.90 | TRPM8 (0.69) | TRPM8L3MBTL1SMN1; SMN2LMNAMAPT | |
| SCHEMBL1443092 | 0.87 | TRPM8 (0.66) | TRPM8L3MBTL1SMN1; SMN2LMNAMAPT | |
| SCHEMBL1442984 | 0.86 | TRPM8 (0.67) | TRPM8L3MBTL1SMN1; SMN2LMNAMAPT | |
| SCHEMBL11900357 | 0.86 | TRPM8 (0.71) | TRPM8L3MBTL1SMN1; SMN2LMNAMAPT | |
| SCHEMBL23837648 | 0.85 | TRPM8 (0.73) | TRPM8L3MBTL1SMN1; SMN2LMNAMAPT | |
| SCHEMBL11900956 | 0.84 | TRPM8 (0.65) | TRPM8L3MBTL1SMN1; SMN2LMNAMAPT | |
| SCHEMBL1442185 | 0.84 | TRPM8 (1.00) | TRPM8L3MBTL1SMN1; SMN2LMNAMAPT | |
| SCHEMBL13471386 | 0.82 | TRPM8 (1.00) | TRPM8L3MBTL1SMN1; SMN2LMNAMAPT | |
| SCHEMBL19186401 | 0.82 | TRPM8 (1.00) | TRPM8L3MBTL1SMN1; SMN2LMNAMAPT | |
| SCHEMBL10270352 | 0.82 | TRPM8 (1.00) | TRPM8L3MBTL1SMN1; SMN2LMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2473486-B2 | PYRIMIDINES AS HEPCIDINE ANTAGONISTS | VIFOR INT AG (CH) | 2021-09-22 | — | — | EP | disclosed |
| EP-2473486-B2 | PYRIMIDINES AS HEPCIDINE ANTAGONISTS | VIFOR INT AG (CH) | 2021-09-22 | — | — | EP | disclosed |
| EP-2473486-B1 | PYRIMIDINES AS HEPCIDINE ANTAGONISTS | VIFOR INT AG (CH) | 2015-10-28 | — | — | EP | disclosed |
| EP-2473486-B1 | PYRIMIDINES AS HEPCIDINE ANTAGONISTS | VIFOR INT AG (CH) | 2015-10-28 | — | — | EP | disclosed |
| US-20120202806-A1 | Novel Pyrimidine- And Triazine-Hepcidine Antagonists | VIFOR (INTERNATIONAL) AG (CH) | 2012-08-09 | — | — | US | disclosed |
| US-20120202806-A1 | Novel Pyrimidine- And Triazine-Hepcidine Antagonists | VIFOR (INTERNATIONAL) AG (CH) | 2012-08-09 | — | — | US | disclosed |
| US-20120202806-A1 | Novel Pyrimidine- And Triazine-Hepcidine Antagonists | VIFOR (INTERNATIONAL) AG (CH) | 2012-08-09 | — | — | US | disclosed |
| EP-2473486-A1 | NOVEL PYRIMIDINE AND TRIAZINE HEPCIDINE ANTAGONISTS | VIFOR (INTERNATIONAL) AG (CH) | 2012-07-11 | — | — | EP | disclosed |
| WO-2011026835-A1 | NOVEL PYRIMIDINE AND TRIAZINE HEPCIDINE ANTAGONISTS | VIFOR (INTERNATIONAL) AG (CH) | 2011-03-10 | — | — | WO | disclosed |
| WO-2011026835-A1 | NOVEL PYRIMIDINE AND TRIAZINE HEPCIDINE ANTAGONISTS | VIFOR (INTERNATIONAL) AG (CH) | 2011-03-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120202806-A1 | Novel Pyrimidine- And Triazine-Hepcidine Antagonists | HAMP, DHPS, SLC40A1 | TRPM8 2345/4885L3MBTL1 3829/4885SMN1; SMN2 4562/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.